Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Medartis Holding AG ( (CH:MED) ) is now available.
Medartis Holding AG has announced a webcast presentation of its half-year results for 2025, scheduled for August 19, 2025. The event will feature presentations by CEO Matthias Schupp and CFO Dirk Kirsten, and will be available for viewing via MS Teams. This announcement signifies Medartis’s commitment to transparency and engagement with stakeholders, providing insights into its financial performance and strategic direction.
The most recent analyst rating on (CH:MED) stock is a Buy with a CHF86.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.
More about Medartis Holding AG
Medartis, founded in 1997 and headquartered in Basel, Switzerland, is a leading global manufacturer and supplier of medical products for the surgical fixation of bone fractures in the upper and lower extremities and the cranio-maxillofacial region. The company employs around 1200 people across 13 locations and distributes its innovative titanium implants and instruments in over 50 countries, focusing on providing high-quality service to surgeons and operating room staff.
Average Trading Volume: 4,364
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.2B
Find detailed analytics on MED stock on TipRanks’ Stock Analysis page.